Department of Gastrointestinal Surgery, Yixing People Hospital, Affiliated Jiangsu University, 214200, China.
Department of Medical Examination Center, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, 214200, China.
Future Oncol. 2017 Dec;13(29):2691-2696. doi: 10.2217/fon-2017-0426. Epub 2017 Oct 3.
We aimed to investigate a practical profile of MAC30 on chemotherapeutic response in gastric cancer (GC).
PATIENTS & METHODS: We elected 87 GC patients receiving platinum-based chemotherapy in this study. MAC30 levels in tumor and adjuvant nontumor tissues were confirmed via reverse transcription-PCR to identify the clinical profile in GC and the correlation with therapeutic response.
We found elevated MAC30 in GC compared with the matched adjacent nontumor tissues. GC with enhanced MAC30 exhibited poorer survival by Kaplan-Meier analysis and poor response to adjuvant platinum-based chemotherapy. A multivariate analysis showed that MAC30 was an independent prognostic factor of overall survival in GC receiving platinum-based chemotherapy.
MAC30 could play as a potential biomarker for prognosis of GC with platinum-based chemotherapy.
我们旨在研究 MAC30 在胃癌（GC）化疗反应中的实用特征。
本研究中我们选择了 87 例接受铂类化疗的 GC 患者。通过逆转录-PCR 确定肿瘤和辅助非肿瘤组织中的 MAC30 水平，以确定 GC 中的临床特征及其与治疗反应的相关性。
我们发现 GC 中的 MAC30 水平高于匹配的相邻非肿瘤组织。通过 Kaplan-Meier 分析发现，MAC30 增强的 GC 患者生存较差，对辅助铂类化疗反应不良。多因素分析表明，MAC30 是接受铂类化疗的 GC 患者总生存的独立预后因素。
MAC30 可能成为 GC 铂类化疗预后的潜在生物标志物。
